<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28444097</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2317-6385</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Einstein (Sao Paulo, Brazil)</Title><ISOAbbreviation>Einstein (Sao Paulo)</ISOAbbreviation></Journal><ArticleTitle>Chronic polyarthritis as the first manifestation of childhood systemic polyarteritis nodosa.</ArticleTitle><Pagination><StartPage>96</StartPage><EndPage>99</EndPage><MedlinePgn>96-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1679-45082017RC3783</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1679-45082017000100096</ELocationID><Abstract><AbstractText>Arthritis has been reported as an acute pattern, generally evanescent with oligoarthritis, mostly affecting knees and ankles in childhood systemic polyarteritis nodosa. However, chronic polyarthritis with morning stiffness mimicking juvenile idiopathic arthritis has not been reported. We describe the case of a 4-year old girl who had additive and chronic polyarthritis with edema, tenderness, pain on motion and morning stiffness for 2 months. After 45 days, she also presented painful subcutaneous nodules and erythematous-violaceous lesions in the extensor region of upper and lower limbs. She was admitted to university hospital due to high fever, malaise, myalgia, anorexia, loss of weight (1kg), painful skin lesions and severe functional disability. She was bedridden by chronic polyarthritis with limitation on motion. Systolic and diastolic blood pressures were greater than 95th percentile for height. Urine protein/creatinine ratio was 0.39g/day, and immunological tests were negative. Anti-streptolysin O was 1,687UI/mL. Skin biopsy revealed necrotizing vasculitis in medium- and small-sized vessels compatible with polyarteritis nodosa. Therefore, we had the diagnosis of systemic polyarteritis nodosa. Prednisone 2mg/kg/day was administered with complete resolution of skin lesions and arthritis, and improvement of proteinuria (0.26g/day) after 15 days. The diagnosis of childhood systemic polyarteritis nodosa should be considered for patients with chronic polyarthritis associated to cutaneous vasculitis triggered by streptococcal infection. RESUMO Na poliarterite nodosa sist&#xea;mica pedi&#xe1;trica, a artrite caracteriza-se pelo padr&#xe3;o agudo, geralmente evanescente, com oligoartrite, e afeta principalmente joelhos e tornozelos. No entanto, a poliartrite cr&#xf4;nica com rigidez matinal e simulando artrite idiop&#xe1;tica juvenil ainda n&#xe3;o foi relatada. Descrevemos o caso de uma menina de 4 anos que apresentou poliartrite cr&#xf4;nica aditiva com edema, dor &#xe0; palpa&#xe7;&#xe3;o e movimento, e rigidez matinal por 2 meses. Ap&#xf3;s 45 dias, tamb&#xe9;m apresentou n&#xf3;dulos subcut&#xe2;neos dolorosos e les&#xf5;es erit&#xea;mato-viol&#xe1;ceas na regi&#xe3;o extensora dos membros superiores e inferiores. Foi internada no hospital universit&#xe1;rio por conta de febre alta, mal-estar, mialgia, anorexia, perda de peso (1kg), les&#xf5;es de pele muito dolorosas e incapacidade funcional grave. Estava restrita ao leito devido &#xe0; poliartrite cr&#xf4;nica com limita&#xe7;&#xe3;o do movimento. Press&#xf5;es sist&#xf3;lica e diast&#xf3;lica foram maiores que percentil 95 para altura. Rela&#xe7;&#xe3;o prote&#xed;na/creatinina urin&#xe1;ria estava 0,39g/dia, e os testes imunol&#xf3;gicos foram negativos. Antiestreptolisina O era 1.687UI/mL. A bi&#xf3;psia de pele revelou vasculite necrosante de vasos de pequeno e m&#xe9;dio calibre, compat&#xed;vel com poliarterite nodosa. Portanto, foi realizado o diagn&#xf3;stico de poliarterite nodosa sist&#xea;mica. Foi administrada prednisona 2mg/kg/dia com resolu&#xe7;&#xe3;o completa das les&#xf5;es de pele e da artrite, al&#xe9;m de melhora da protein&#xfa;ria (0,26g/dia) ap&#xf3;s 15 dias. O diagn&#xf3;stico de poliarterite nodosa sist&#xea;mica pedi&#xe1;trica deve ser considerado em pacientes com poliartrite cr&#xf4;nica associado a les&#xf5;es cut&#xe2;neas vascul&#xed;ticas, sendo a infec&#xe7;&#xe3;o estreptoc&#xf3;cica um importante fator desencadeante.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Glaucia Vanessa</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Instituto da Crian&#xe7;a, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Koken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Instituto da Crian&#xe7;a, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampa</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Instituto da Crian&#xe7;a, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okumura</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Instituto da Crian&#xe7;a, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Gabriela Ribeiro Viola</ForeName><Initials>GRV</Initials><AffiliationInfo><Affiliation>Instituto da Crian&#xe7;a, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Clovis Artur</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Instituto da Crian&#xe7;a, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Einstein (Sao Paulo)</MedlineTA><NlmUniqueID>101281800</NlmUniqueID><ISSNLinking>1679-4508</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004890" MajorTopicYN="N">Erythema</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010488" MajorTopicYN="N">Polyarteritis Nodosa</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040521" MajorTopicYN="N">Subcutaneous Tissue</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText>Na poliarterite nodosa sist&#xea;mica pedi&#xe1;trica, a artrite caracteriza-se pelo padr&#xe3;o agudo, geralmente evanescente, com oligoartrite, e afeta principalmente joelhos e tornozelos. No entanto, a poliartrite cr&#xf4;nica com rigidez matinal e simulando artrite idiop&#xe1;tica juvenil ainda n&#xe3;o foi relatada. Descrevemos o caso de uma menina de 4 anos que apresentou poliartrite cr&#xf4;nica aditiva com edema, dor &#xe0; palpa&#xe7;&#xe3;o e movimento, e rigidez matinal por 2 meses. Ap&#xf3;s 45 dias, tamb&#xe9;m apresentou n&#xf3;dulos subcut&#xe2;neos dolorosos e les&#xf5;es erit&#xea;mato-viol&#xe1;ceas na regi&#xe3;o extensora dos membros superiores e inferiores. Foi internada no hospital universit&#xe1;rio por conta de febre alta, mal-estar, mialgia, anorexia, perda de peso (1kg), les&#xf5;es de pele muito dolorosas e incapacidade funcional grave. Estava restrita ao leito devido &#xe0; poliartrite cr&#xf4;nica com limita&#xe7;&#xe3;o do movimento. Press&#xf5;es sist&#xf3;lica e diast&#xf3;lica foram maiores que percentil 95 para altura. Rela&#xe7;&#xe3;o prote&#xed;na/creatinina urin&#xe1;ria estava 0,39g/dia, e os testes imunol&#xf3;gicos foram negativos. Antiestreptolisina O era 1.687UI/mL. A bi&#xf3;psia de pele revelou vasculite necrosante de vasos de pequeno e m&#xe9;dio calibre, compat&#xed;vel com poliarterite nodosa. Portanto, foi realizado o diagn&#xf3;stico de poliarterite nodosa sist&#xea;mica. Foi administrada prednisona 2mg/kg/dia com resolu&#xe7;&#xe3;o completa das les&#xf5;es de pele e da artrite, al&#xe9;m de melhora da protein&#xfa;ria (0,26g/dia) ap&#xf3;s 15 dias. O diagn&#xf3;stico de poliarterite nodosa sist&#xea;mica pedi&#xe1;trica deve ser considerado em pacientes com poliartrite cr&#xf4;nica associado a les&#xf5;es cut&#xe2;neas vascul&#xed;ticas, sendo a infec&#xe7;&#xe3;o estreptoc&#xf3;cica um importante fator desencadeante.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28444097</ArticleId><ArticleId IdType="pmc">PMC5433315</ArticleId><ArticleId IdType="doi">10.1590/S1679-45082017RC3783</ArticleId><ArticleId IdType="pii">S1679-45082017000100096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145(4):517&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">15480378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) EULAR/PRINTO/PRES criteria for Henoch-Sch&#xf6;nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">20413568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes RC, Marques VL, Cavalcante EG, Campos LM, Sallum AM, Tannuri U, et al. Severe intestinal involvement as initial manifestation of systemic childhood polyarteritis nodosa: report of two cases. J Pediatr Surg. 2013;48(2):425&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">23414878</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques VL, Guariento A, Sim&#xf5;es MS, Blay G, Lotito AP, Silva CA. Childhood-onset systemic polyarteritis nodosa and systemic lupus erythematosus: an overlap syndrome? Rev Bras Reumatol Engl Ed. 2016;56(6):551&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">27914603</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcini F, La Torre F, Vittadello F, Rigante D, Martini G, Corona F, et al. Clinical overview and outcome in a cohort of children with polyarteritis nodosa. Clin Exp Rheumatol. 2014;32(3) Suppl 82:S134&#x2013;S137.</Citation><ArticleIdList><ArticleId IdType="pubmed">24529184</ArticleId></ArticleIdList></Reference><Reference><Citation>Siberry GK, Cohen BA, Johnson B. Cutaneous polyarteritis nodosa. Reports of two cases in children and review of the literature. Arch Dermatol. 1994;130(7):884&#x2013;889. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">7912919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos F, Figueira R, Fonseca J, Canh&#xe3;o H, Mouzinho P, Valente P, et al. Juvenile cutaneous polyarteritis nodosa associated with streptococcal infection. Acta Reum Port. 2006;31(1):83&#x2013;88. Portuguese.</Citation><ArticleIdList><ArticleId IdType="pubmed">17058387</ArticleId></ArticleIdList></Reference><Reference><Citation>David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69(6):685&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1029656</ArticleId><ArticleId IdType="pubmed">7904442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcante EG, Aikawa NE, Lozano RG, Lotito AP, Jesus AA, Silva CA. Chronic polyarthritis as the first manifestation of juvenile systemic lupus erythematosus patients. Lupus. 2011;20(9):960&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">21636626</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27084269</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1885-1398</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin</ISOAbbreviation></Journal><ArticleTitle>Vitamin D insufficiency and deficiency in mexican patients with systemic lupus erythematosus: Prevalence and relationship with disease activity.</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>101</EndPage><MedlinePgn>97-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reuma.2016.02.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1699-258X(16)00046-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine and compare the prevalence of vitamin D insufficiency and deficiency in patients with systemic lupus erythematosus (SLE) with and without disease activity.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We made a comparative, observational, cross-sectional, prospective study of 137 women with SLE according to American College of Rheumatology criteria. Patients with chronic kidney disease, cancer, hyperparathyroidism, pregnancy, and lactation were excluded. Disease activity was assessed using the MEX-SLEDAI score: a score of &#x2265;3 was considered as disease activity. Data were collected on diabetes mellitus, the use of corticosteroids, chloroquine, and immunosuppressants, photoprotection and vitamin D supplementation. Vitamin D levels were measured by chemiluminescent immunoassay: insufficiency was defined as serum 25-hydroxyvitamin D &lt;30ng/ml and deficiency as &lt;10ng/ml.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">137 women with SLE (mean age 45.9&#xb1;11.6 years, disease duration 7.7&#xb1;3.4 years) were evaluated. Mean disease activity was 2 (0-8): 106 patients had no disease activity and 31 had active disease (77.4% versus 22.6%). Vitamin D insufficiency and deficiency was found in 122(89.0%) and 4 (2.9%) patients, respectively. There was no significant difference in vitamin D levels between patients with and without active disease (19.3&#xb1;4.5 versus 19.7&#xb1;6.8; P=.75). No correlation between the MEX-SLEDAI score (P=.21), photosensitivity, photoprotection, prednisone or chloroquine use and vitamin D supplementation was found.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Women with SLE had a high prevalence of vitamin D insufficient. No association between vitamin D levels and disease activity was found.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Reumatolog&#xed;a y Colegio Mexicano de Reumatolog&#xed;a. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Carrasco</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico; Departamento de Reumatolog&#xed;a e Inmunolog&#xed;a, Facultad de Medicina, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Puebla, M&#xe9;xico. Electronic address: mgc30591@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza-Pinto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico; Departamento de Reumatolog&#xed;a e Inmunolog&#xed;a, Facultad de Medicina, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etchegaray-Morales</LastName><ForeName>Ivet</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto-Santill&#xe1;n</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Herrera</LastName><ForeName>Erick Alejandro</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robles-S&#xe1;nchez</LastName><ForeName>Viridiana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Gallegos</LastName><ForeName>Alma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratorios Cl&#xed;nicos de Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Varela</LastName><ForeName>Araceli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Autoinmunes Sist&#xe9;micas, Hospital General Regional N.(o) 36, Instituto Mexicano del Seguro Social, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Guarneros</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Secretar&#xed;a de Estudios de Posgrado e Investigaci&#xf3;n, Facultad de Medicina, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Arg&#xfc;elles</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratorios Cl&#xed;nicos de Puebla, Puebla, M&#xe9;xico; Universidad de las Am&#xe9;ricas Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Insuficiencia y deficiencia de vitamina D en pacientes mexicanas con lupus eritematoso sist&#xe9;mico: prevalencia y relaci&#xf3;n con actividad de la enfermedad.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin</MedlineTA><NlmUniqueID>101293923</NlmUniqueID><ISSNLinking>1699-258X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014808" MajorTopicYN="N">Vitamin D Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deficiencia</Keyword><Keyword MajorTopicYN="N">Deficiency</Keyword><Keyword MajorTopicYN="N">Insufficiency</Keyword><Keyword MajorTopicYN="N">Insuficiencia</Keyword><Keyword MajorTopicYN="N">Lupus eritematoso sist&#xe9;mico</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Vitamin D</Keyword><Keyword MajorTopicYN="N">Vitamina D</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27084269</ArticleId><ArticleId IdType="doi">10.1016/j.reuma.2016.02.013</ArticleId><ArticleId IdType="pii">S1699-258X(16)00046-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25739480</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Print"><Volume>151</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>[Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital].</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>26</EndPage><MedlinePgn>20-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Non-melanoma skin cancer (NMSC) is the most common malignancy in transplant patients. The incidence of basal cell carcinoma (BCC) is 10 times greater than in the general population, while squamous cell carcinoma (SCC) is 100 times greater. The relationship between the BCC and SCC reverses and increases according to the degree of immunosuppression and sun exposure. One way to predict the risk of NMSC should be based on factors such as: total sun burden factor (TSB).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the influence of various risk factors in the development of NMSC and its relation to the type and duration of immunosuppressive treatment, type of transplant, and TSB.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We worked with a fledgling historical cohort in which patients with kidney or liver transplant were identified and recorded if they developed some form of skin cancer. To study the factors associated with NMSC, we resorted to the strategy of a case-control study. Dermatological examination was performed and a questionnaire of risk factors made in both groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 140 patients enrolled, 51 were women and 89 men, 120 were renal transplant recipients and 20 liver transplants. Of patients who developed NMSC, 100% were renal transplant recipients. The median age was 48.5 years. Most cancer patients worked outdoors. A total of 78 lesions were found in 40 NMSC patients, 59 (76%) of them were SCC, and 19 (24%) BCC; 45% of all skin cancer patients had more than one injury. The worst affected areas were those photoexposed: 60% head and neck, trunk and upper extremities 18% 50%. In 30% of patients (12/40) 22 new tumors were identified (SCC 18 and BCC 4). No lesions were identified for melanoma. In multivariate logistic regression analysis, statistically significant features were: type-based immunosuppressive regimen of cyclosporine A, azathioprine and prednisone (OR: 59.7; 95% CI: 10.2-348), TSB &gt; 10 (OR: 19; 95% CI: 3-120) and duration of use of immunosuppressive therapy (OR: 1.06; 95% CI: 0.9-1.1). The mean time from transplantation to first dermatological assessment was six years (+5.4). Of the patients, 93% had not regularly used sunscreen before and after transplantation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The dermatological assessment is convenient and easy to perform. Primary prevention, close monitoring, diagnosis, and treatment of skin lesions are essential components of a comprehensive program for the evaluation of transplant recipients, the purpose of which is to reduce the incidence and morbidity associated with cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Acosta</LastName><ForeName>Elva Dalia</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Departamento de Infectolog&#xed;a, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n &#xab;Salvador Zubir&#xe1;n&#xbb; (INCMNSZ), M&#xe9;xico, D.F.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calva-Mercado</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Departamento de Infectolog&#xed;a, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n &#xab;Salvador Zubir&#xe1;n&#xbb; (INCMNSZ), M&#xe9;xico, D.F.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alber&#xfa;-G&#xf3;mez</LastName><ForeName>Josefina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Trasplantes, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n &#xab;Salvador Zubir&#xe1;n&#xbb; (INCMNSZ), M&#xe9;xico, D.F.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilatoba-Chapa</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Trasplantes, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n &#xab;Salvador Zubir&#xe1;n&#xbb; (INCMNSZ), M&#xe9;xico, D.F.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez-Cherit</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Dermatolog&#xed;a; Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n &#xab;Salvador Zubir&#xe1;n&#xbb; (INCMNSZ), M&#xe9;xico, D.F.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Pacientes con trasplante de &#xf3;rgano s&#xf3;lido y c&#xe1;ncer de piel: determinaci&#xf3;n de factores de riesgo con &#xe9;nfasis en la fotoexposici&#xf3;n y el esquema inmunosupresor. Experiencia de un hospital de tercer nivel.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013473">Sunscreening Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002280" MajorTopicYN="N">Carcinoma, Basal Cell</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016377" MajorTopicYN="N">Organ Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013472" MajorTopicYN="N">Sunlight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013473" MajorTopicYN="N">Sunscreening Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25739480</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22401733</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>[Proliferative mesangial lupus nephritis: description of a cohort of 27 patients].</ArticleTitle><Pagination><StartPage>341</StartPage><EndPage>345</EndPage><MedlinePgn>341-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2011.12.017</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">To describe our cohort of 27 biopsy-proven patients and their long-term follow-up, with special attention to prognostic factors.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Twenty seven patients were retrospectively collected. They were controlled in the Internal Medicine Department of the Bellvitge's Hospital (Spain) between 1974 and 2010. Evaluation was performed at one, 3 and 5 year follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 22 women (81.5%). Mean age at onset of nephritis was 34.83 years (SD 13.45). Partial or complete remission was achieved by 21 patients (80.77%) in the one-year follow-up, 22 patients (84.61%) in the third-year follow-up and 21 patients (77.77%) in the fifth-year follow-up. A change in the histology class was diagnosed in 4 patients. Seven patients suffered flares of nephritis. Seven patients died in the long term follow-up, 3 out of this 7 died because of systemic erythematosus lupus.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nephritis onset beyond 45 years old is the factor mostly related with a poor prognosis. That is the reason why we recommend co-therapy with immunosuppressors from the beginning in such patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Espa&#xf1;a, S.L. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubio-Rivas</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Unidad de Enfermedades Autoinmunes, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Espa&#xf1;a. mrubiorivas@yahoo.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Junyent</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mitjavila</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Capdevila</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Pujol</LastName><ForeName>Ram&#xf3;n</ForeName><Initials>R</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Nefritis l&#xfa;pica mesangial proliferativa: descripci&#xf3;n de una cohorte de 27 pacientes.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22401733</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2011.12.017</ArticleId><ArticleId IdType="pii">S0025-7753(12)00055-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20505627</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2010</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2184-8777</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Acta reumatologica portuguesa</Title><ISOAbbreviation>Acta Reumatol Port</ISOAbbreviation></Journal><ArticleTitle>[Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients].</ArticleTitle><Pagination><StartPage>36</StartPage><EndPage>41</EndPage><MedlinePgn>36-41</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the prevalence of traditional risk factors in patients with primary antiphospholipid syndrome (APS) in comparison to those with systemic lupus erythematosus-secondary APS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Transversal study of 96 APS patients (Sapporo's criteria). Demographic and clinical data, cardiovascular risk factors and drug use were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine Primary APS and 57 secondary APS were included. The groups did not differ regarding age (38.5 +/- 9.9 vs. 39.4 +/- 10.5 years, p=0.84) and female gender (84.6 vs. 96.5%, p=0.06), respectively. Arterial events were more observed in primary than secondary APS (59 vs. 36.8%, p=0.04) patients. No difference was seen concerning venous and obstetric events. In regard to traditional risk factors for cardiovascular disease, both groups were comparable related to current or previous smoking, sedentarism, family history for coronary disease, systemic hypertension, diabetes mellitus, overweight and obesity. The frequencies of altered lipid profiles were alike in the two groups, except for a higher prevalence of low HDL-c levels in primary APS group (84.6 vs. 45.5%, p=0.0001). Concerning drug use, no significant differences were observed related to chloroquine and statin use, however the secondary APS patients had a higher rate of prednisone use (10.2 vs. 57.9%, p&lt;0.001) as well as mean dose of corticosteroid (1.5 +/- 5.7 vs. 9.2 +/- 12.5mg/ /day, p=0.0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Traditional risk factors for cardiovascular disease are present and comparable between patients with primary and secondary APS, except for a high frequency of low HDL-c in primary APS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>A R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Reumatologia do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, SP. jotafc@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Fatores de risco tradicionais para doen&#xe7;a cardiovascular na s&#xed;ndrome antifosfol&#xed;pide 36 prim&#xe1;ria comparada &#xe0; secund&#xe1;ria: um estudo de 96 pacientes.</VernacularTitle></Article><MedlineJournalInfo><Country>Portugal</Country><MedlineTA>Acta Reumatol Port</MedlineTA><NlmUniqueID>0431702</NlmUniqueID><ISSNLinking>0303-464X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="N">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20505627</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">21794672</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1885-1398</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin</ISOAbbreviation></Journal><ArticleTitle>[Damage in cuban patients with systemic lupus erythematosus. Relation with disease features].</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>15</EndPage><MedlinePgn>11-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reuma.2009.04.007</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine damage presence and predictors factors for its appearance in a cohort of cuban patients with systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A retrospective cohort study included 80 patients presenting with SLE seen in Rheumatology Service of "Hermanos Ameijeiras" Clinical Surgical Hospital in Havana City, Cuba. Damage was assessed using The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index (SLIC/ACR), a tool approved for damage measurement. Damage presence was related to initial disease features to diagnose this condition, to sociodemographic elements, to treatments used, and to the disease course time. Statistical analysis had two variants: the univariate and multivariate type using Chi2 and statistical significance was established in p&lt;0, 05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that 39 patients (48,8%) had some degree of damage. More involved domains were the musculoskeletal (18,8%), neuropsychiatric, and skin, 16,3%, pulmonary and ocular, present in 15% of cases. In the multivariate analysis, damage was associated with the use of higher than 30 mg/day Prednisone doses for more of 4 weeks (OR=54,68, CI 95%=3,56-97,45, p=0.001), presence of leukopenia (RO=18,73, CI 95%=2,74-62,23m p=0,004), and time course of disease (OR=1,02, CI 95%=1,00 2-1,09, p=0.006).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Damage was practically present in half of the study patients, the most involved domain was the musculoskeletal, and use of higher than 30mg prednisone doses were the factor most associated with the presence of damage.</AbstractText><CopyrightInformation>Copyright &#xa9; 2008 Elsevier Espa&#xf1;a, S.L. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Est&#xe9;vez Del Toro</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Hospital Hermanos Ameijeiras, Ciudad de La Habana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chico Capote</LastName><ForeName>Araceli</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hechavarr&#xed;a</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez Paneque</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kokuina</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Da&#xf1;o en pacientes cubanos con lupus eritematoso sist&#xe9;mico. Relaci&#xf3;n con caracter&#xed;sticas de la enfermedad.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin</MedlineTA><NlmUniqueID>101293923</NlmUniqueID><ISSNLinking>1699-258X</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21794672</ArticleId><ArticleId IdType="doi">10.1016/j.reuma.2009.04.007</ArticleId><ArticleId IdType="pii">S1699-258X(09)00156-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>